PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signalling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signalling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signalling.
Introduction
Activation of class 1 phosphoinositide 3-kinase (PI3K) occurs following ligation of a plethora of leukocyte receptors that are responsible for innate and adaptive immune responses [1] [2] [3] .
Activation of PI3K results in the addition of a phosphate group to its lipid substrate PI(4,5)P 2 , forming PI(3,4,5)P 3 in the cell surface membrane. PI(3,4,5)P 3 initiates a variety of signalling cascades by interaction with pleckstrin homology (PH) domain containing proteins, most notably the serine kinase Akt [4] .
Class 1A isoforms (PI3Kα, PI3Kβ and PI3Kδ) are activated by receptor tyrosine kinases, whilst the Class 1B isoform PI3Kγ is activated following GPCR ligation. However, these definitions are proving less rigid than previously thought. For example, PI3Kβ has been shown to signal downstream of GPCR activation [5] , whilst activation of the Class 1B isoform PI3Kγ has been reported by receptor tyrsosine kinases and TLR/IL-1Rs [6] . PI3Kγ has also been reported to participate in T-cell-receptor signalling [7] . The PI3Kα and PI3Kβ isoforms appear to have a broad tissue distribution, while PI3Kδ and PI3Kγ are primarily expressed in leukocytes. Studies using mice in which the genes encoding PI3Kδ or PI3Kγ have been either altered to encode kinase-inactive mutants (e.g. PI3Kδ 
Development of PI3K inhibitors to target the immune system: lessons from PI3Kδ
The strong evidence of a role of dysregulated PI3Kγ and PI3Kδ in immune-mediated pathologies, has prompted intense efforts to develop selective inhibitors of these isoforms.
The first compounds to block PI3K-the natural product wortmannin and Lilly's Ly294002
were reported in the early 1990's and served as useful experimental tools to research the PI3K pathway [2] . This is evidenced by nearly 6000 PUBMed hits for Ly294002 alone. However, the usefulness of wortmannin and Ly294002 both as research tools and potential drugs was tempered by their broad targeting of all PI3K isoforms and off-target effects [10] . However, the simple planar structure of Ly294002 (Figure 1 ) has aided the design of more selective pan-PI3K and isoform specific inhibitors. In particular, crystal structures of PI3Ks bound to Ly294002, have facilitated huge advances in the design of PI3K inhibitors which utilize the regions of the ATP binding pocket to achieve greater potency and selectivity as well as reduced toxicity [11] [12] [13] Compounds that selectively inhibit PI3Kγ have been identified, with a series of compounds designed by Merck Serono SA based on the thiazolidinedione scaffold. One of these, AS-605240 (Figure 1 ), exhibited superior potency compared to related compounds, can be administered orally and has high cell membrane permeability [14] . However, the subsequent development of PI3Kγ inhibitors for the treatment of inflammatory disorders in humans has been largely disappointing. This is most likely due to the selectivity achieved for PI3Kγ over other class 1A PI3K isoforms, being insufficient to avoid off-target effects. In contrast, the development and implementation of inhibitors which target the PI3Kδ isoform has proven more successful. The discovery of the quinazolinone purine series, exemplified by the ICOS compound IC-87114 (Figure 1 ) demonstrated that the design of isoform selective PI3K
inhibitors with at least 50-fold potency over other isoforms was possible to achieve [15] . SHIP-1 as an alternative target for modulation of PI3K signaling.
Role of SHIP in the immune system
The development of isoform specific PI3K inhibitors for inflammatory disease, particularly toward PI3K, has been disappointing. This has lead to the search for alternative targets with which to modulate PI3K signalling specifically in the immune system. In this regard, attention has recently focussed on the lipid phosphatase SH2-domain containing inositol-5-phosphatase (SHIP), which de-phosphorylates PI(3,4,5)P 3 at the D5 position of the inositol ring to create PI(3,4)P 2 . Multiple forms of SHIP have been reported, but the 145 kDa SHIP-1 (Figure 2 ) is a particularly ideal target for development of potential therapeutics for treating immune disorders. This is because its hematopoietic-restricted expression would limit the impact of SHIP-1 targeted drugs to the immune system. One would predict for example, that activators of SHIP-1 would lead to a reduction of cellular PI(3,4,5)P 3 levels and hence, mimic the effect of PI3K inhibitors. SHIP-1 was initially considered as a negative regulator of PI3K signalling. However, the SHIP-1 product PI(3,4)P 2 is itself recognized by some PH domaincontaining proteins [24] . Thus SHIP-1 can act as a molecular 'switch', re-directing PI3K signalling away from PI(3,4,5)P 3 -dependent effector proteins, towards proteins which bind exclusively or partially to PI(3,4)P 2 . 
SHIP-1 is

The Role of SHIP-1 in leukemia
Over-activation of PI3K-dependent signalling cascades is a common occurrence in many human cancers [32] . The lipid phosphatase PTEN which also negatively regulates PI(3,4,5)P 3 accumulation by de-phosphorylating the D3 position of the inositol ring, is a well characterized tumour suppressor gene [33] . Likewise, evidence for mutations of SHIP-1 have also been shown in acute lymphoblastic leukaemia [34] and in acute myeloid leukaemia [35] .
SHIP-1 is targeted by miR-155 in B cells, with high levels of miR-155 and reduced SHIP-1 expression linked to the development of acute lymphoblastic leukaemia in mice [36] . miR-155 levels were also found to be significantly increased in human patients with diffuse large B cell lymphoma [37] . The loss of SHIP-1 has been shown to promote the development of erythroleukemia, with SHIP-1 identified as a target gene of the oncogene fli-1 [38] . The loss of SHIP-1 has been shown to promote the development of erythroleukemia, with SHIP-1 identified as a target gene of the oncogene fli-1 [38] . The role of SHIP-1 as a tumour suppressor is also evident in the ability of SHIP-1 to restrict myeloid suppressor cells and regulatory T cells [30, 39] . Therefore the loss of SHIP-1 expression/ function may lead to increased suppression of T-cell mediated anti-tumour immunity. Indeed, in murine pancreatic cancer SHIP-1 expression was shown to be reduced in splenocytes which also correlated with an increase in myeloid suppressor cell numbers [40] . Decreased SHIP-1 expression has also been shown in myelodysplastic syndrome progenitor cells, where over-expression of SHIP-1 inhibited myeloid leukemic growth [41] .
The role of SHIP-1 in leukemia however, appears more complex than initially thought. For example, SHIP-1 was shown not to act as a tumour suppressor in myeloma cells [42] . The use of a small molecule SHIP-1 inhibitor demonstrated that catalytically active SHIP-1 is required for the survival of multiple myeloma cells [43] and that therefore, in certain cases, SHIP-1 actually supports cancer cell survival. This would be consistent with increased levels of the SHIP-1 enzymatic product PI(3,4)P 2 promoting Akt activation and survival/proliferation [44] .
Indeed another group has shown that SHIP-1 inhibits CD95/Fas-mediated apoptosis of T cells [45] .
Pharmacological Targeting of SHIP
Allosteric SHIP-1 activators:
The identification and description of an activator of SHIP-1, termed pelorol, was first described in 2005 and was derived from the marine invertebrate Dactylospongia elegans [46] .
Aquinox Pharmaceuticals designed more potent synthetic analogies AQX-MN100 and AQX-016A (Figure 1 ) which along with PI(3,4)P 2 , were shown to allosterically enhance catalytic activity by binding to the C2 domain of SHIP-1 (Figure 2) . AQX-016A and AQX-MN100
showed potent inhibition of immune cell activation in vitro and were anti-inflammatory in vivo using mouse models of endotoxemia and acute cutaneous anaphylaxis [47] . Intriguingly, 
SHIP-1 inhibitors
A novel small molecule selective inhibitor of SHIP-1, termed 3 α-aminocholestane (3AC, Figure 1 ) has also recently been identified using high throughput screening, although the site of action is currently unclear [43] . Consistent with observations from SHIP-1 deficient mice, treatment of mice with 3AC led to increased numbers of myeloid suppressor cells and reduced ability of peripheral lymphoid tissues to prime myeloid-associated responses and protected against Graft-versus-host disease [43] . The inhibition of SHIP-1 using pharmacological compounds may therefore offer the potential to aid transplant acceptance in patients undergoing transplant surgery. 3AC also increased levels of granulocytes, red blood cells, neutrophils and platelets in mice and could therefore, have potential to improve blood cell number in patients with myelodysplastic syndrome or myelosuppressive infection.
Remarkably, SHIP-1 inhibition using 3AC induced the apoptosis of human AML cell lines which is consistent with SHIP-1 being anti-apoptotic under some circumstances [43] . 
SHIP-2 inhibitors
SHIP-2 shares 35% homology with SHIP-1, and is thought to be involved in type-2 diabetes and obesity [51] . Its ubiquitous expression means that it is also expressed in leukocytes and one concern is that inhibition of SHIP-1 will be compensated for by SHIP-2. In recent years 
Summary
The β, γ and δ isoforms of PI3K have important non-redundant roles in multiple cells of the immune system. Consequently alterations of the PI3K signaling pathway can lead to inflammatory and autoimmune disorders as well as leukemia. This, together with growing appreciation of the crystal structure of the catalytic isoforms which help define the structure-activity rules for obtaining selectivity, will spur the continued design and development of improved PI3K inhibitors. These offer opportunities to manipulate the PI3K signaling network in immune cells for inflammation and transplantation as well as cancer. The latter may include non-leukemic cancers, given the up-regulation of PI3Kγ and PI3Kδ in some forms of non-immune cell malignancies [32, 55, 56] . One concern would be that it might be difficult to avoid effects on the immune system that could impair the endogenous anti-tumor response.
The difficulties of developing PI3Kγ inhibitors with sufficient selectivity over PI3K isoforms has in part, led to the exploitation of endogenous and leukocyte-restricted regulators of PI3K signaling, namely the lipid phosphatase SHIP-1. Small molecule regulators of this protein have shown early promise in inflammatory, transplantation and cancer settings, and are currently in phase I clinical trials to evaluate the safety, tolerability and pharmacokinetics (Table 1) . However, the targeting of SHIP-1 (particularly with inhibitors), is not without its problems. For example, SHIP-1 deficiency leads to a number of pathologies including fibrotic lung disease [57] , osteoporosis [58] and the development of Crohn's disease-like ileitis [59] .
Another point to take into account when pharmacologically targeting SHIP-1, is the fact that SHIP-1 has important non-catalytic functions [60] . Therefore inhibition of the catalytic site of SHIP-1 may not be sufficient to inhibit SHIP-1 mediated modulation of PI3K activity in all cases.
References: . SHIP also has a C2 domain adjacent to the catalytic domain which, when bound to PI(3,4)P2, acts to allosterically enhance the catalytic activity of SHIP [47] . Loss of anergy, production of auto-antibodies [64] Myeloid cell Increased myeloid suppressor cell numbers [39] Increased M2 macrophage skewing (indirect mechanism via increased IL-4 secretion from basophils) [65] Increased ratio of PI(3,4,5)P 3 to PI(3,4)P 2 on phagosomal membrane.
Decreased early NADPH oxidative activity in phagosomes [66] Dendritic cell Enhanced survival and proliferation, but impaired maturation [67] Reduced nitric oxide production; SHIP null DC's suppress T cell proliferation [68] Natural Killer cells Deficient receptor repertoire. Defective IFNγ secretion. Increase in peripheral number. Defective cytolytic function. [69] .
